Latika Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-07-2024
- Paid Up Capital ₹ 0.10 M
as on 30-07-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5.22%
(FY 2023)
- Profit -13.77%
(FY 2023)
- Ebitda -13.25%
(FY 2023)
- Net Worth -13.15%
(FY 2023)
- Total Assets 10.97%
(FY 2023)
About Latika Biotech
The Corporate was formerly known as Latika Bio-Tech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Latika Bajoria, Akash Bajoria, and Sarvesh Bajoria serve as directors at the Company.
- CIN/LLPIN
U24100WB2014PTC201866
- Company No.
201866
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Latika Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Latika Bajoria  | Director | 23-May-2014 | Current |
| Akash Bajoria | Director | 23-May-2014 | Current |
| Sarvesh Bajoria | Director | 04-Nov-2014 | Current |
Financial Performance of Latika Biotech.
Latika Biotech Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.22% increase. The company also saw a substantial fall in profitability, with a 13.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Latika Biotech?
In 2023, Latika Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Latika Infotech Private LimitedActive 13 years 5 monthsLatika Bajoria, Akash Bajoria and 1 more are mutual person
- E.M. Bypass Medical Centre Private LimitedActive 25 years 5 months
Latika Bajoria, Akash Bajoria and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Latika Biotech?
Latika Biotech has a workforce of 8 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Latika Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Latika Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
